 A PHASE I, OPEN LABEL, NON RANDOMIZED, MULTICENTER, DOSE ESCALATION CLINICAL STUDY TO INVESTIGATE SAFETY AND TOLERABILITY OF OPBOTSUKA PHARMACEUTICAL BIWA-111077 IN SUBJECTS WITH ADVANCED HCCHEPATOCELLULAR CARCINOMA: 